DGCI approves Psoriasis injection Itolizumab for 'restricted emergency use' to treat COVID

India's drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, officials told PTI on Friday.

Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India, Dr V G Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon, for restricted emergency use for the treatment of "cytokine'' release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.

READ | Coronavirus Live Updates: India's COVID Tally Crosses 8-lakh Mark; 1.1 Cr Samples Tested

READ | UP Board To Reduce Syllabus In View Of COVID-19, Says Dy CM Taking Cue From CBSE Board

"The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome," an official told PTI.

"It is already an approved drug of Biocon for treating psoriasis for last many years," the official said.

Written informed consent of each patient is required before the use of this drug, he said.

READ | WHO Clears Air On 'unknown Pneumonia' In Kazakhstan As China Calls It Deadlier Than COVID

READ | WHO Chief Says COVID-19 Outbreaks Can Be Brought Under Control, Cites India's Example